FDA Oncology Announcements

Anti-BCMA ADC × Clear all

3 Announcements

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma

Trial: DREAMM 7
Drug: Blenrep (belantamab mafodotin-blmf) · Anti-BCMA antibody-drug conjugate
Condition: Plasma cell

FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma

Drug: Blenrep (belantamab mafodotin-blmf) · Anti-BCMA antibody-drug conjugate
Condition: Plasma cell

FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma

Drug: Blenrep (belantamab mafodotin-blmf) · Anti-BCMA antibody-drug conjugate
Condition: Plasma cell